Endostar + cyclophosphamide + doxorubicin + vincristine + prednisone

Endostar + cyclophosphamide + doxorubicin + vincristine + prednisone is a multi-agent combination regimen used in oncology, particularly for the treatment of certain cancers such as non-small cell lung cancer and nasopharyngeal carcinoma. This regimen combines Endostar (recombinant human endostatin), an antiangiogenic biologic that inhibits tumor blood vessel formation primarily by blocking vascular endothelial growth factor (VEGF) signaling, with four established chemotherapeutic agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA and induces apoptosis. - Doxorubicin, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. - Vincristine, a vinca alkaloid that disrupts microtubule formation during mitosis. - Prednisone, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. The combination aims to enhance antitumor efficacy through complementary mechanisms—targeting both tumor vasculature (via Endostar) and directly killing cancer cells or inhibiting their proliferation (via chemotherapy). Endostar is notable for its improved stability and biological activity compared to native endostatin[1][3]. The overall mechanism involves inhibition of angiogenesis, induction of cell cycle arrest at various phases depending on the agent used, direct cytotoxicity to tumor cells, disruption of mitosis, and modulation of immune responses[3].